A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.

doi:10.1158/1078-0432.CCR-25-4080

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2026

Chen Jiaying, Oberheim Bush Nancy Ann, Grabowsky Jennifer A, Kline Cassie, Kroetz Deanna L, Taylor Jennie W, Villanueva-Meyer Javier, Molinaro Annette M, de Groot John F, Butowski Nicholas A, Tedesco Meghan, Rabbitt Jane, Phillips Joanna J, Hervey-Jumper Shawn, Aghi Manish K, Berger Mitchel S, Chang Edward F, Chang Susan M, Solomon David A, Clarke Jennifer L

Abstract excerpt

PURPOSE: Existing salvage therapies for recurrent glioblastoma (rGBM) have limited efficacy, with a median survival of approximately 9 months. Given the complex molecular heterogeneity of GBM, single-target approaches have consistently failed as a treatment strategy. We conducted a phase I clinical trial to assess the feasibility, safety, and efficacy of a genomically tailored multiagent regimen in 30 adults with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Brain Neoplasms

Share to Genomics

Share to Glioblastoma

Share to Neoplasm Recurrence, Local

Share to Precision Medicine

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41649856
DOI: 10.1158/1078-0432.CCR-25-4080
PMCID: PMC13133611

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.PMID 41649856Read ↗

Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.Semantic proximity Read ↗

One size should not fit all: advancing toward personalized glioblastoma therapy.Semantic proximity Read ↗

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.Semantic proximity Read ↗

Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in GlioblastomaSemantic proximity Read ↗

Toward precision medicine in glioblastoma: the promise and the challenges.Semantic proximity Read ↗

Personalized medicine for glioblastoma: current challenges and future opportunities.Semantic proximity Read ↗

Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?Semantic proximity Read ↗

Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma.Semantic proximity Read ↗

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.Semantic proximity Read ↗

Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.Semantic proximity Read ↗

Intratumoral Heterogeneity and Longitudinal Changes in Gene Expression Predict Differential Drug Sensitivity in Newly Diagnosed and Recurrent GlioblastomaSemantic proximity Read ↗

Single‐cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug‐resistance mechanisms of recurrent glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.